Strong Collaboration Between Chinese Cardiovascular Companies to Build a Comprehensive Heart Failure Treatment Solution Across the Full Disease Cycle

Jul 19, 2025 22:15 CST Updated 22:15

BrioHealth Solutions

Ventricular Assist Device Developer and Manufacturer

Shenqi Medical

Cardiovascular Interventional Device Developer

BrioHealth Solutions and Shenqi Medical Jointly Announce Strategic Cooperation to Integrate Their Respective Advantageous Resources, with a product matrix of "artificial heart + ultrafiltration technology" to drive the upgrade of the advanced heart failure diagnosis and treatment service system, building solutions covering early intervention to end-stage support for heart failurePatients are provided with more comprehensive and precise treatment options.。

BrioHealth Solutions is a leader in artificial hearts (left ventricular assist devices) in China, with its product CH-VAD implantable left ventricular assist device.The system is approved by the NMPA as theALeft Ventricular Assist Device. And completed in November last year.In the United StatesFirst CaseNew Generation Left Ventricular Assist Device (BrioVAD)Clinical Research (INNOVATE ) Enrollment (This is the first clinical study of an active implantable product from China conducted in the U.S.）。

Shenqi Medical is an innovative company covering multiple fields of cardiovascular and cerebrovascular diseases. Its current main focus areas include cardiovascular intervention, structural heart disease, peripheral vascular intervention, and neurovascular intervention. ShenqiIn 2020, BrioHealth Solutions strategically invested in Beijing Hartkell Medical Technology Co., Ltd., which is the first company in China to research, develop, and produce ultrafiltration treatment devices for heart failure.HartKel's ultrafiltration product ---- the heart failure ultrafiltration dehydration device was approved for marketing by NMPA in 2017.

BrioHealth Solutions' Left Ventricular Assist Device is mainly applicable toEnd-stage heart failure,Bringing important hope to patients for extending life and improving quality of life.

HartKel'sHeart Failure Ultrafiltration Dehydration Device MainlyFor issues such as excessive volume load during the acute phase,Heart Failure Ultrafiltration Dehydration DeviceCan provide a safe and efficient alternative when diuretics are not effective, effectively stabilizing hemodynamics.

The collaboration between the two parties will create a synergistic effect in heart failure treatment and provide fromComprehensive Solutions from Early to End-Stage Heart Failure, for Heart FailureProvide patients with more comprehensive and precise treatment optionsIn addition to the synergies in treatment, HartKel's heart failure ultrafiltration dehydration device can leverage the influence of BrioHealth Solutions in the field of heart failure treatment, allowing more doctors and patients to learn about it.Heart failure ultrafiltration dehydration device, therebyHeart failure ultrafiltration dehydration device brought to more hospitals, ultimately improvingHeart Failure Ultrafiltration Dehydration DevicePenetration rate.

Introduction to Heart Failure Ultrafiltration Dehydration Device

Heart Failure Ultrafiltration Dehydration DeviceIt is a specialized dehydration device solely for heart failure. An extracorporeal circulation pathway is established via the veins, powered by a blood pump, creating an extracorporeal blood circulation through a filter. Under the negative pressure suction of the ultrafiltration pump, ultrafiltrate is formed through the filter and continuously, real-time monitored by a weighing scale to ensure safe, controllable, and predictable ultrafiltration dehydration. Compared with traditional blood purification, heart failure ultrafiltration dehydration does not require replacement fluid, has minimal impact on hemodynamics, and demonstrates better safety in therapeutic applications.

Currently, ultrafiltration treatment for heart failure has been included in clinical guidelines. According to the "Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024," ultrafiltration therapy can be considered for patients with high volume overload, such as pulmonary edema or severe peripheral edema, and diuretic resistance (Ⅱa, B).